CrossRef Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Young Hoon Youn, Su Jung Baik, Hye Sun Lee, Hyun Wook Chae Frontiers in Endocrinology .2025;[Epub] CrossRef Soft drink consumption and liver fibrosis in type 2 diabetes Arianna Ferro, Martina Bollati, Gian Paolo Caviglia, Angelo Armandi, Stefania Bellini, Selene Limoncelli, Giulio Mengozzi, Federica Barutta, Fabio Broglio, Guglielmo Beccuti, Elisabetta Bugianesi, Marilena Durazzo, Gabriella Gruden Frontiers in Nutrition .2025;[Epub] CrossRef Artificial intelligence applications for managing metabolic dysfunction-associated steatotic liver disease: Current status and future prospects Jian-Jun Lou, Jing Zeng World Journal of Gastroenterology .2025;[Epub] CrossRef Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus Virginia Markoutsaki, Georgios Dimakopoulos, Emmanouil Sinakos, Kalliopi Kotsa, Theocharis Koufakis Hormones .2025;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study Chan Kyeol Kim, Sangyong Jo, Kyupin Ha, Bongjo Kim, Hyeon Ji Kim, Sang Yi Moon, Byoung-Gwon Kim, Kyungil Park, Jong Sung Park, Young Rak Cho, Tae-Ho Park, Kyunghee Lim, Minkook Son Heart .2025
Going from evidence to recommendations: the significance and presentation of recommendations
The mechanism of action involves multiple interconnected pathways that facilitate tissue regeneration and vascular repair
With over 50 different wellness prescriptions and therapies available at the practice, peptides are one component of a larger treatment toolkit
While he supports insurance coverage to help people with obesity access treatment, he cautions against the perception that GLP-1s are a miracle drug
Tirzepatide has shown remarkable efficacy in managing blood sugar levels
